CODEN: WJAPAC Impact Factor: 3.87 ISSN: 3049-3013

World Journal of Advance Pharmaceutical Sciences

Volume 2, Issue 1. Page: 186-190 Review Article www.wjaps.com

BALCHATURBHADRA: THE WONDER DRUG IN AYURVEDA FOR CHILDREN

Dr. Sushant Bhandari[1*] and Dr. Achyut Acharya[2]

[1]Consultant Ayurveda Physician, Shrikhanda Ayurveda Centre, Kathmandu, Nepal.
[2]PG Scholar, Department of Roga Nidana Evam Vikriti Vigyana, National Institute of Ayurveda, Jaipur, Rajasthan.

How to cite this Article Dr. Sushant Bhandari and Dr. Achyut Acharya (2025). *BALCHATURBHADRA*: THE WONDER DRUG IN AYURVEDA FOR CHILDREN. World Journal of Advance Pharmaceutical Sciences, 2(1), 186-190.

Article Info

Article Received: 29 April 2025,

Article Revised: 19 May 2025,

Article Accepted: 09 June 2025.

DOI: https://doi.org/10.5281/zenodo.15641125

***Corresponding author:**

***Dr. Sushant Bhandari**

Consultant Ayurveda Physician, Shrikhanda Ayurveda Centre, Kathmandu, Nepal.

ABSTRACT

Balchaturbhadra, also known as *Balacaturbhadrika Churna*, is a classical Ayurvedic polyherbal formulation widely employed in the management of pediatric ailments. Comprised of four potent herbs—*Musta* (*Cyperus rotundus*), *Pippali* (*Piper longum*), *Ativisha* (*Aconitum heterophyllum*), and *Karkata Sringi* (*Pistacia integerrima*)—this formulation offers a broad spectrum of therapeutic actions. It is particularly effective in treating common childhood conditions such as fever, cough, diarrhea, vomiting, and respiratory tract infections. This review provides a comprehensive evaluation of *Balchaturbhadra*'s traditional indications, pharmacological foundations, formulation characteristics, and its growing relevance within contemporary pediatric healthcare.

KEYWORDS: *Balchaturbhadra*, Pediatric Illness, Ayurveda.

INTRODUCTION

Ayurveda, India's ancient system of medicine, offers a sophisticated pharmacopeia of herbal formulations specifically designed for pediatric care. Among these, *Balchaturbhadra Churna* stands as a cornerstone pediatric remedy with centuries of documented clinical success. This compound formulation, whose name translates to "the four powerful medicines for children," exemplifies Ayurveda's holistic approach to child health. Prepared as a fine powder (*churna*), it combines four potent herbs *Musta* (*Cyperus rotundus*), *Pippali* (*Piper longum*), *Ativisha* (*Aconitum heterophyllum*), and *Karkata Sringi* (*Pistacia integerrima*) each contributing unique therapeutic properties. Revered in classical texts like the *Bhavaprakash*[1], *Sarangadhara Samhita*[2], and *Bhaisajya Ratnavali*[3], *Balchaturbhadra* addresses a spectrum of childhood ailments, from digestive disorders to respiratory infections. In an era where synthetic drugs often carry side effects and antibiotic resistance rises, this ancient formulation offers a gentle yet effective alternative. This review explores *Balchaturbhadra*'s formulation, pharmacological basis, traditional applications, and scientific validation, positioning it as a wonder drug in Ayurvedic pediatrics.

Ayurvedic Pharmacy: The Foundation of *Balchaturbhadra*

Ayurvedic pharmacology (*Bhaishajya Kalpana*) classifies drug preparations into five basic types (*Panchavidha Kashaya Kalpana*):[4]

1. ***Swarasa*** (fresh juice)
2. ***Kalka*** (paste)
3. ***Kwatha*** (decoction)
4. ***Phanta*** (hot infusion)
5. ***Hima*** (cold infusion)

From these, derived preparations (*Upkalpanas*) like *Churna Kalpana* (powders) are developed. *Churna Kalpana*, or powdered formulations, are particularly favored for several practical and therapeutic reasons. Firstly, the preparation process results in negligible wastage, making it an efficient choice for formulation. These powders also have a comparatively longer shelf life—typically ranging from two months to a year—when stored properly, which enhances their usability

over time. Additionally, *Churna* is easy to administer, especially in children, as the fine powder can be conveniently mixed with honey, ghee, or water, making it more palatable and easier to swallow. The small particle size of the powder facilitates rapid dissolution and improves bioavailability, ensuring quicker onset of action and better therapeutic efficacy in pediatric patients.

Balchaturbhadra Churna epitomizes these advantages. According to the *Sarangadhara Samhita*, *churna* is defined as a "nicely powdered dry drug filtered through cloth," administered at 12g doses. Its preparation involves meticulous steps: individual herbs are cleaned, dried, separately powdered to account for differences in hardness, sieved, then mixed homogeneously.[5] Industrial production uses pulverizers and ball mills, but the core principle remains—preserving volatile oils and active compounds.

Balchaturbhadra: Composition and Historical Significance

Balchaturbhadra's formula is fixed: equal parts of four herbs:[6]

1. *Musta* (*Cyperus rotundus* rhizome)
2. *Pippali* (*Piper longum* fruit)
3. *Ativisha* (*Aconitum heterophyllum* root)
4. *Karkata Sringi* (*Pistacia integerrima* galls)

It is extensively documented in authoritative texts:

- *Ayurvedic Formulary of India* (Part 1, 7:24)[7]
- *Bhaisajya Ratnavali* (Balarogadhikara 71/39)
- *Bhavaprakash*, *Yoga Ratnakar*, *Vrinda Madhav*, and others.

Pharmacological Profiles of Key Ingredients

1. *Musta (Cyperus rotundus)*[8]

- **Taxonomy**: Family Cyperaceae; commonly called nutgrass.
- ***Rasapanchaka***
  - *Rasa*: Tikta (bitter), Katu (pungent)
  - *Guna*: Laghu (light), Ruksha (dry)
  - *Vipaka*: Katu (pungent post-digestion)
  - *Veerya*: Sheeta (cooling)
  - *Karma*: Kapha-Pitta reducer; digestive, anti-diarrheal, febrifuge.
- **Phytochemistry**: Rich in sesquiterpenes (cyperene, rotundone), flavonoids, and essential oils with α-pinene and cineole.[9]
- **Pharmacology**[10]
  - **Anti-inflammatory & Analgesic**: Suppresses carrageenan-induced edema.
  - **Antipyretic**: Reduces yeast-induced fever.
  - **Gastroprotective**: Delays gastric motility and protects against ethanol-induced ulcers.
  - **Antimicrobial**: Active against *Staphylococcus aureus*.
- **Pediatric Use**: Treats diarrhea (*Atisara*), vomiting (*Chardi*), and fever (*Jwara*).[11]

2. *Pippali (Piper longum)*[12]

- **Taxonomy**: Family Piperaceae; long pepper.
- ***Rasapanchaka***[13]
  - *Rasa*: Katu (pungent)
  - *Guna*: Laghu (light), Tikshna (sharp)
  - *Vipaka*: Madhura (sweet post-digestion)
  - *Veerya*: Ushna (heating)
  - *Karma*: Respiratory stimulant, digestive, anti-inflammatory.
- **Phytochemistry**: Contains piperine (alkaloid), piplartine, and essential oils (β-caryophyllene).[14]
- **Pharmacology**
  - **Bronchodilator**: Reverses histamine-induced bronchospasm.
  - **Bioenhancer**: Piperine increases drug bioavailability.
  - **Immunomodulatory**: Enhances phagocytosis.
- **Pediatric Use**: Key for *Kasa* (cough), *Swasa* (asthma), and digestive weakness.[15]

3. *Ativisha (Aconitum heterophyllum)*[16]

- **Taxonomy**: Family Ranunculaceae; known as Atis root.
- ***Rasapanchaka***
  - *Rasa*: Tikta (bitter), Katu (pungent)
  - *Guna*: Laghu (light)
  - *Veerya*: Ushna (heating)
  - *Vipaka*: Katu (pungent)
  - *Karma*: Reduces Kapha and Ama (toxins); anti-diarrheal, febrifuge.
- **Phytochemistry**: Non-toxic diterpenoid alkaloids (atisine, atidine).
- **Pharmacology**[17]
  - **Anti-diarrheal**: Inhibits intestinal hypermotility.
  - **Immunomodulatory**: Stimulates macrophage activity.
- **Pediatric Use**: Manages diarrhea, vomiting, and low immunity.[18]

4. *Karkata Sringi (Pistacia integerrima)*

- **Taxonomy**: Family Anacardiaceae; crab's claw galls.
- ***Rasapanchaka***
  - *Rasa*: Kashaya (astringent), Tikta (bitter)
  - *Guna*: Laghu (light), Ruksha (dry)
  - *Veerya*: Ushna (heating)
  - *Karma*: Kapha-Vata reducer; antitussive, anti-asthmatic.
- **Phytochemistry**: Essential oils (α-pinene, camphene), triterpenoids.[19]
- **Pharmacology**
  - **Antitussive**: Suppresses cough reflex.
  - **Anti-inflammatory**: Inhibits paw edema by 30–70%.
- **Pediatric Use**: Addresses cough, asthma, and fever.[20]

Therapeutic Applications in Pediatrics

Balchaturbhadra's strength lies in its synergistic multi-targeting of common childhood conditions:

1. Respiratory Disorders (*Kasa, Swasa*)

- **Mechanism**: *Pippali's* bronchodilator effects combine with *Karkata Sringi's* antitussive action to relieve cough and asthma. Musta's cooling property reduces inflammation.
- **Clinical Use**: Prescribed for bronchitis, allergic asthma, and seasonal coughs.

2. Gastrointestinal Issues (*Atisara, Chardi*)

- **Mechanism**: *Ativisha* and *Musta* halt diarrhea and vomiting via anti-secretory and gut-motility modulation. *Pippali* enhances digestion.[21]
- **Clinical Use**: Effective in viral gastroenteritis, dysentery, and indigestion.

3. Fever (*Jwara*)

- **Mechanism**: *Musta* (antipyretic) and *Ativisha* (detoxifier) reduce fever by resetting thermoregulation and eliminating toxins.

4. Immunity Boosting

- **Mechanism**: *Ativisha* and *Pippali* activate macrophages and modulate Th1/Th2 responses, enhancing innate immunity against infections.[22]

Safety and Dosage

- **Dose**: 250–500 mg, 2x/day with honey, ghee, or warm water.
- **Safety**: Low toxicity (LD_{50} >500 mg/kg in studies). Ativisha is carefully processed to remove toxic aconitine.



Fig. No: 01: Spectrum of therapeutic applications from targeted to broad.

Scientific Validation and Contemporary Relevance

Modern scientific studies increasingly affirm the efficacy of *Balchaturbhadra* in pediatric care. Research has demonstrated its notable antimicrobial properties, showing activity against common pediatric pathogens such as *Escherichia coli* and *Staphylococcus aureus*. These findings support its traditional use in managing infections like diarrhea and respiratory illnesses. Additionally, the formulation exhibits significant anti-inflammatory effects, with evidence pointing to its ability to inhibit cyclooxygenase-2 (COX-2) and histamine-mediated pathways—mechanisms often targeted by conventional anti-inflammatory drugs.[23] Importantly, *Balchaturbhadra* also boasts a favorable safety profile, with studies reporting negligible side effects when compared to synthetic drugs such as antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs). This positions it as a promising natural alternative in pediatric treatment protocols.

The *Balchaturbhadra* formulation aligns closely with emerging global trends in pediatric healthcare, particularly those favoring safe, holistic, and sustainable treatment options. It is gentle yet effective, offering therapeutic benefits without contributing to major modern concerns such as antibiotic resistance or gut dysbiosis—issues increasingly associated with the overuse of conventional drugs. Its holistic mode of action not only targets presenting symptoms but also supports foundational physiological functions by strengthening digestion (*Agni*) and enhancing immunity (*Ojas*), key concepts in Ayurvedic medicine. Moreover, the formulation is highly cost-effective, making it an accessible option for large-scale use in pediatric populations, especially in resource-limited settings.

Challenges and Future Directions

Despite its therapeutic potential, *Balchaturbhadra* faces several challenges that limit its broader acceptance and integration into modern pediatric healthcare. One of the primary concerns is the issue of standardization, as variations in the quality of raw herbs and inconsistencies in processing methods can lead to fluctuations in efficacy and safety. Additionally, there is a significant lack of pharmacokinetic data, particularly regarding the absorption, distribution, metabolism, and excretion (ADME) of the formulation, which is essential for understanding its behavior within the body. Furthermore, regulatory barriers pose another hurdle, largely due to the absence of well-designed, pediatric-specific clinical trials that could provide robust scientific validation for its use in children. Addressing these issues is crucial for establishing *Balchaturbhadra* as a reliable and evidence-based pediatric remedy.

To fully harness the therapeutic potential of *Balchaturbhadra* in pediatric care, several key research priorities must be addressed. Foremost among these is the need for rigorous clinical trials, particularly randomized controlled trials (RCTs), to evaluate its efficacy in common childhood conditions such as diarrhea, pneumonia, and fever. These studies would provide the scientific validation necessary for wider clinical acceptance. Additionally, mechanistic studies are essential to explore the formulation's role in immune modulation and its interactions with the gut microbiome—areas that could reveal deeper insights into its holistic mode of action. Innovation in formulation techniques is another important frontier, with the development of nano-*churnas* offering the promise of enhanced bioavailability, faster onset of action, and improved patient compliance. Together, these research initiatives can bridge traditional knowledge with modern scientific standards, paving the way for *Balchaturbhadra*'s integration into contemporary pediatric therapeutics.

CONCLUSION

Balchaturbhadra Churna embodies Ayurveda's wisdom in pediatric care—a blend of four powerful herbs refined over centuries into a safe, broad-spectrum remedy. Its success against respiratory, digestive, and febrile disorders underscores its epithet as a "wonder drug" for children. As modern medicine grapples with antimicrobial resistance and chemical side effects, this ancient formulation offers a time-tested, holistic alternative. Future research must bridge traditional knowledge and contemporary science through rigorous validation, ensuring *Balchaturbhadra*'s place in integrative pediatrics. For the health of our children, it is not just a relic of the past but a beacon for the future.

REFERENCES

1. Mishra, B. (1980) *Bhava Prakasa* of Shri Bhavamishra, Chaukhambha Samskrta Samsthana, Varanasi, 808.
2. Sharma, P. (1985) *Sarangadhara Samhita* of Pandit Sarangadharacharya, Chaukhambha Amarabharti Prakashan, Varanasi, 172-175.
3. Shastri, A. (1983) *Bhaishajya Ratnavali* of Shri Govinda Dasa, Balarogadhikara, Chaukhambha Samskrta Samsthana, Varanasi, 747.
4. Reddy, K. R. C. (1998) *Bhaisajya Kalpana Vijnanam*, Chaukhambha Sanskrit Bhawan, Varanasi, 235-242.
5. Sharma, P. (1985) *Sarangadhara Samhita* of Pandit Sarangadharacharya, Chaukhambha Amarabharti Prakashan, Varanasi, 172-175.
6. Shastri, A. (1983) *Bhaishajya Ratnavali* of Shri Govinda Dasa, Balarogadhikara 71/39, Chaukhambha Samskrta Samsthana, Varanasi.
7. Anonymous (1998) The Ayurvedic Formulary of India, Part-I, Govt. India, Ministry of Health and Family Planning, Deptt. of Health, India, 92.
8. Anonymous (2001) *The Ayurvedic Pharmacopoeia of India*, Part-I and Volume-III, Ministry of Health and Family Welfare, Govt. of India, New Delhi (*C. rotundus, pp.129-130*).
9. Thebtaranonth, C., Thebtranonth, Y., Wanauppaathamkul, S. and Yuthavong, Y. (1995) Antimalarial sesquiterpenes from tubers of *Cyperus rotundus*: Structure of 10, 12-Peroxycalamenene, a sesquiterpene endoperoxide, *Phytochemistry, 40(1):* 125.
10. Patel, H. K. (1993) *Investigations of the Commercial Sample of Motha and their comparison with Cyperus rotundus*, M. Pharm Thesis, Gujarat University, Ahmedabad, India.
11. Sharma, P. V. and Sharma, G. P. (1982) *Dhanvantari Nighantu* of Dhanvantari, Chaukhambha Orientalis, Varanasi, India (*C. rotundus, p.23; P. longum, p.83; A. heterophyllum, p.18; P. integerrima, p.31*).
12. Shastri, A. (1968) *Sushruta Samhita* of Sushruta, Chaukhambha Sanskrit Bhavan, Varanasi (*C. rotundus, p.197; P. longum, p.203*).
13. Sharma, P. V. (2001) *Dravyaguna Vijnana*, Chaukhambha Bharti Academy, Varanasi, Vol.-2 (*C. rotundus, p.371; P. longum, p.277; A. heterophyllum, p.356; P. integerrima, p.285*).
14. Shastri, B. K. and Shastri, V. L. (1936) *Nighantu Ratnakar*, Part-I, Niryan Sagar, Mumbai (*C. rotundus, p.102; P. longum, p.130*).
15. Sharma, P. V. and Sharma, G. P. (1982) *Dhanvantari Nighantu* of Dhanvantari, Chaukhambha Orientalis, Varanasi, India (*C. rotundus, p.23; P. longum, p.83; A. heterophyllum, p.18; P. integerrima, p.31*).
16. Metcalfe, C. R., Chalk, L. (1950) *Anatomy of the Dicotyledons*, Oxford at the Clerendon Press (*P. longum, p.224; A. heterophyllum, p.101; P. integerrima, p.109*).
17. Jadhavji Trikamji Acharya (1950) Dravyaguna Vijnana, Part 2, Niryana Sagar Press, Bombay (*A heterophyllum*, p. 63, *P. integerrima*, p. 154).
18. Sharma, P. V. and Sharma, G. P. (1982) *Dhanvantari Nighantu* of Dhanvantari, Chaukhambha Orientalis,

Varanasi, India (*C. rotundus, p.23; P. longum, p.83; A. heterophyllum, p.18; P. integerrima, p.31*).
19. Ansari, S. H., Mohd. Ali, Velasco-Negueruela, A., Perez - Alonso, M. J. (1998) Volatile constituents of the galls and stem bark of *Pistacia integerrima* stew. ex Brandis, *Journal of Essential Oil Research, 10(3):* 313-316 CR through *MAPA, 1998; 20(6):* 691.
20. Sharma, P. V. and Sharma, G. P. (1982) *Dhanvantari Nighantu* of Dhanvantari, Chaukhambha Orientalis, Varanasi, India (*C. rotundus, p.23; P. longum, p.83; A. heterophyllum, p.18; P. integerrima, p.31*).
21. Valani, G. K. (199888) *A comparative pharmaco-clinical study of Pippali Churna and Pippali Ghrita on Amlapitta*, M. D. Thesis, Gujarat Ayurved University, Jamnagar.
22. Bhattacharya, S.K. (1981) In: *Studies on the effects of some antimalarials on immune mechanism in experimental animals*, M.D. Thesis, Delhi University, Delhi.
23. Talwar, G.P. (1983) *A Handbook of Practical Immunology*, Vikas Publishing House Pvt. Ltd., New Delhi, p. 36.